$GRFS News

Plasma Demand Supports Grifols, S.A.’s (GRFS) Path Back to Financial Strength

Are Options Traders Betting on a Big Move in Grifols Stock?

Grifols (BME:GRF) Stock May Be Below Fair Value On Earnings

GRFS vs. SDZNY: Which Stock Should Value Investors Buy Now?

Grifols: Better Plasma Economics Can Unlock A Discounted Equity

GRFS or SDZNY: Which Is the Better Value Stock Right Now?

OPSEU/SEFPO: Permanently end for-profit plasma collection to protect public health

FOXO TECHNOLOGIES INC.’S SUBSIDIARY VECTOR BIOSOURCE, INC. ENTERS INTO DEFINITIVE AGREEMENT TO ACQUIRE FOUR BLOOD COLLECTION CENTERS FROM GRIFOLS BIO SUPPLIES, INC.

Grifols (GRFS) Q2 2026 Earnings Call Transcript

Grifols SA (GRFS) (H1 2026) Earnings Call Highlights: Strong Biopharma Growth and Strategic ...

Grifols Q2 Earnings Call Highlights

Grifols Doses First Participants In Two Separate Phase 3 Studies To Expand U.S. Labels For Its GAMUNEX-C, XEMBIFY Subcutaneous Immunoglobulin

Grifols (GRFS) Launches FESILTY in the U.S. for Congenital Fibrinogen Deficiency Treatment

Grifols: Plasma Self-Sufficiency Is The Mispriced Catalyst

Grifols, S.A. (GRFS) Sees Strong Biopharma Growth Led by Gamunex and Yimmugo

Grifols Q1 Earnings Call Highlights

Grifols Q1 Revenue €1.7 Billion Down From €1.786 Billion YoY

Is Grifols (BME:GRF) A Potential Opportunity After A 59% Five Year Share Price Slide

'Grifols' Canadian License Restricted After Plasma Donor Deaths' - Bloomberg

Grifols' Chronos-PD Study Demonstrates That Biological Changes In Individuals With Parkinson's Disease Occur More Than A Decade Before Clinical Diagnosis, With Potential Future Implications For Early Detection And Intervention